Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial

Journal of Alzheimer's Disease : JAD
José A LuchsingerEmilia Bagiella

Abstract

Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). We conducted a pilot study of metformin, a medication efficacious in treating and preventing diabetes while reducing hyperinsulinemia, among persons with amnestic mild cognitive impairment (aMCI) with the goal of collecting preliminary data on feasibility, safety, and efficacy. Participants were 80 men and women aged 55 to 90 years with aMCI, overweight or obese, without treated diabetes. We randomized participants to metformin 1000 mg twice a day or matching placebo for 12 months. The co-primary clinical outcomes were changes from baseline to 12 months in total recall of the Selective Reminding Test (SRT) and the score of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). The secondary outcome was change in relative glucose uptake in the posterior cingulate-precuneus in brain fluorodeoxyglucose positron emission tomography. Change in plasma Aβ42 was an exploratory outcome. The mean age of participants was 65 years. Fifty percent of participants were women. The only baseline variable that was different between the arms was the ADAS-Cog. Metformin could not be tolerated by 7.5% of participants; 15% tolerated 500 mg/day, 35% toler...Continue Reading

Associated Clinical Trials

Feb 21, 2008·José A. Luchsinger, José A. Luchsinger

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Feb 29, 1996·The New England Journal of Medicine·C J Bailey, R C Turner
Mar 12, 1997·JAMA : the Journal of the American Medical Association·D A SnowdonW R Markesbery
Mar 8, 2000·American Journal of Public Health·W J StrawbridgeS J Shema
Mar 29, 2000·JAMA : the Journal of the American Medical Association·D J Selkoe
Jul 6, 2000·Annals of Internal Medicine·R A DeFronzo
Sep 23, 2000·The Journal of Neuropsychiatry and Clinical Neurosciences·D I KauferS T DeKosky
Jul 11, 2001·Neuroscience and Biobehavioral Reviews·C R Park
Feb 8, 2002·The New England Journal of Medicine·William C KnowlerUNKNOWN Diabetes Prevention Program Research Group
Apr 23, 2002·Human Mutation·J Ross HawkinsThomas A Weaver
Oct 25, 2002·The New England Journal of Medicine·David M Nathan
Mar 14, 2003·Proceedings of the National Academy of Sciences of the United States of America·Wesley FarrisSuzanne Guenette
Mar 29, 2003·Diabetes Care·UNKNOWN Diabetes Prevention Program Research Group
Aug 29, 2003·The American Journal of Cardiology·Cheng-Yang TuanGerald Reaven
Sep 27, 2003·Journal of the American Geriatrics Society·Richard B LiptonHerman Buschke
Jan 21, 2004·Archives of Neurology·Michael GrundmanUNKNOWN Alzheimer's Disease Cooperative Study
Apr 20, 2004·European Journal of Pharmacology·G Stennis Watson, Suzanne Craft
Jul 2, 2004·The New England Journal of Medicine·Jeffrey L Cummings
Aug 25, 2004·Journal of Internal Medicine·R C Petersen
Sep 10, 2004·The New England Journal of Medicine·Hannele Yki-Järvinen
Oct 13, 2004·Neurology·Jose A LuchsingerRichard Mayeux
Apr 15, 2005·The New England Journal of Medicine·Ronald C PetersenUNKNOWN Alzheimer's Disease Cooperative Study Group
Apr 20, 2005·Annals of Internal Medicine·Trevor J OrchardUNKNOWN Diabetes Prevention Program Research Group
Apr 28, 2005·Diabetes·Steven HaffnerUNKNOWN Diabetes Prevention Program Research Group
Nov 16, 2005·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·G Stennis WatsonSuzanne Craft
Feb 1, 2006·The Pharmacogenomics Journal·M E RisnerUNKNOWN Rosiglitazone in Alzheimer's Disease Study Group
Mar 1, 2006·Transplantation Proceedings·A ChudykS Giedrys-Kalemba
Apr 6, 2006·JAMA : the Journal of the American Medical Association·Cynthia L OgdenKatherine M Flegal
Dec 6, 2006·The New England Journal of Medicine·Steven E KahnUNKNOWN ADOPT Study Group

❮ Previous
Next ❯

Citations

Jun 16, 2016·Cell Metabolism·Nir BarzilaiMark A Espeland
May 14, 2017·Diabetes Care·José A LuchsingerUNKNOWN Diabetes Prevention Program Research Group
Feb 20, 2018·Diabetes, Obesity & Metabolism·Stephanie Claire BridgemanCyril Desire Sylvain Mamotte
Apr 25, 2018·CNS Neuroscience & Therapeutics·Igor PomytkinTatyana Strekalova
Oct 6, 2018·British Journal of Clinical Pharmacology·Sam AminFinbar O'Callaghan
Mar 5, 2019·Current Alzheimer Research·Firas H BazzariHanan S El-Abhar
Jan 30, 2018·Nature Reviews. Neurology·Steven E ArnoldDavid M Nathan
Mar 22, 2019·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Jing ZhangXiaochun Chen
Aug 5, 2017·Diabetologia·Willy Marcos ValenciaHermes Florez
Nov 22, 2019·Reviews in the Neurosciences·Bor Luen Tang
Jun 4, 2020·Antioxidants & Redox Signaling·Germán Plascencia-Villa, George Perry
Nov 30, 2018·BMJ Open Diabetes Research & Care·Jacqueline M McMillanAlexander A Leung
Mar 10, 2017·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Cláudia Y SantosJessica Alber
Jun 29, 2017·Journal of Diabetes Research·Grazia Daniela FemminellaNicola Ferrara
May 11, 2018·Frontiers in Neuroscience·Christian Benedict, Claudia A Grillo
Nov 25, 2017·Current Geriatrics Reports·Gladys E Maestre
Nov 6, 2018·Molecular Medicine Reports·Xiuzhen HaoHuixiao Dong
May 10, 2019·Frontiers in Aging Neuroscience·Christian Hölscher
Mar 4, 2020·CNS & Neurological Disorders Drug Targets·Anamaria Jurcau, Aurel Simion
Jul 28, 2020·Nature Reviews. Drug Discovery·Stephen C CunnaneMark J Millan
Jun 29, 2018·Frontiers in Neuroscience·Shreyasi Chatterjee, Amritpal Mudher
Aug 29, 2018·Journal of Alzheimer's Disease : JAD·Jared M CampbellEdoardo Aromataris
Feb 19, 2019·Journal of Alzheimer's Disease : JAD·Alberto Serrano-Pozo, John H Growdon
May 2, 2018·Journal of Alzheimer's Disease : JAD·Jung Hyun LeeKelly T Dineley
Jun 27, 2019·Journal of Psychopharmacology·Teodoro Del SerMiguel A Fernández-Blázquez
Aug 4, 2018·Frontiers in Endocrinology·Carola RotermundJulia C Fitzgerald
Oct 26, 2018·International Journal of Molecular Sciences·Andrea TumminiaLucia Frittitta
Apr 9, 2020·Frontiers in Pharmacology·Nurul Husna IbrahimJaya Kumar
Sep 10, 2020·International Journal of Molecular Sciences·Jong Youl KimJong Eun Lee
Dec 12, 2020·Behavioural Brain Research·Meixiang ChenFeng Jin
Nov 6, 2020·Diabetes & Metabolism·Anthony P Sunjaya, Angela F Sunjaya
Jan 31, 2021·CNS Drugs·Manfred Hallschmid
Nov 5, 2020·Mechanisms of Ageing and Development·Samir Morsli, Ilaria Bellantuono

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
ELISA

Clinical Trials Mentioned

NCT00620191

Related Concepts

Related Feeds

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.